title: Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration.
abstract: Abciximab occasionally causes severe thrombocytopenia. This is variable in severity and usually occurs within hours of administration but has been reported to present up to 8 days later. This report describes a case of life-threatening thrombocytopenia 16 days following Abciximab administration. The patient required supportive transfusions and ultimately improved following dexamethasone and intravenous immunoglobulin. The case represents the longest delay between Abciximab administration and thrombocytopenia published to date.
authors.affiliation: Royal Berkshire Hospital, London Road, Reading, RG1 5AN, UK.
authors.forename: G J
authors.initials: GJ
authors.lastname: Webb
authors.forename: J M A
authors.initials: JM
authors.lastname: Swinburn
authors.forename: H
authors.initials: H
authors.lastname: Grech
mesh_terms: D000077284:Abciximab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous; D003907:Dexamethasone / Q000627:therapeutic use; D017707:Erythrocyte Transfusion; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010976:Platelet Count; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D016756:Immunoglobulins, Intravenous; D010975:Platelet Aggregation Inhibitors; D003907:Dexamethasone; D000077284:Abciximab